Methylphenidate Extended-release Tablet, Orally Disintegrating
NDC Package 62542-100-31
Package Information
Methylphenidate Extended-release tablets is a medication used to treat attention deficit hyperactivity disorder - ADHD. This formulation utilizes a tablet, orally disintegrating delivery system. Marketed by Neos Therapeutics, Lp, this product is identified by NDC 62542-100 and is authorized under FDA application NDA205489.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 62542 - Neos Therapeutics, Lp
- 62542-100 - Methylphenidate Extended-release
- 62542-100-31 - 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE
- 62542-100 - Methylphenidate Extended-release
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 62542-100-31 identifies a specific commercial package of 30 tablet, orally disintegrating in 1 bottle of Methylphenidate Extended-release, a human prescription drug labeled by Neos Therapeutics, Lp. This tablet, orally disintegrating is formulated for oral use and contains methylphenidate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Neos Therapeutics, Lp on July 01, 2026. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This medication is used to treat attention deficit hyperactivity disorder - ADHD. It works by changing the amounts of certain natural substances in the brain. Methylphenidate belongs to a class of drugs known as stimulants. It can help increase your ability to pay attention, stay focused on an activity, and control behavior problems. It may also help you to organize your tasks and improve listening skills.
How is this Neos Therapeutics, Lp product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 62542010031. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.